Skip to content
OpenCapital
Get started

Pulmonx Corporation LUNG Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-43.7%
Enterprise value$50.17M-39.2%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value?
Pulmonx Corporation (LUNG) reported share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value of $0 in Q1 2026.
How has Pulmonx Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value changed year-over-year?
Pulmonx Corporation's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value decreased by 100.0% year-over-year, from $3.4M to $0.